#USA #New York #Nuvation Bio #IBTROZI #safusidenib

Nuvation Bio's Q1 2026 Financial Results and Business Developments

Nuvation Bio Inc. has proudly announced its financial results for the first quarter of 2026, marking a significant phase in the company’s journey in oncology. With a strong focus on addressing the challenges of cancer care, Nuvation Bio’s continued progress with its flagship product, IBTROZI® (taletrectinib), emphasizes its commitment to enhancing treatment options for patients battling ROS1-positive non-small cell lung cancer (NSCLC).

Financial Highlights

In Q1 2026, Nuvation Bio registered $18.5 million in net product revenues from IBTROZI, demonstrating the drug's increasing demand and acceptance among practitioners and patients. Notably, a majority of the approximately 200 patients who began treatment with IBTROZI during this quarter were TKI-naïve, underscoring the treatment's recognition as a viable first-line option.

The company showcased its robust financial health, reporting $533.7 million in cash, cash equivalents, and marketable securities by March 31, 2026. This solid base prepares Nuvation Bio for future investments in research and development, as well as for potential acquisition opportunities.

Clinical Advancements

At the 2026 American Association for Cancer Research (AACR) Annual Meeting, Nuvation Bio presented updated clinical data, reinforcing the drug's durability of response. The results from the TRUST-I and TRUST-II studies highlighted remarkable clinical efficacy, showing an impressive 89.8% confirmed objective response rate (cORR) among TKI-naïve patients. Furthermore, the data revealed a median duration of response (mDOR) of 49.7 months and a median progression-free survival (mPFS) of 46.1 months.

Nuvation Bio's commitment to improving patient outcomes is further validated by the recent inclusion of IBTROZI in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for systemic therapy in ROS1-positive NSCLC with brain metastases, marking a pivotal moment in the treatment landscape.

Strategic Acquisitions

A notable development during this quarter is the acquisition of rights to safusidenib from Daiichi Sankyo, granting Nuvation Bio exclusive global development and commercialization rights. Safusidenib is an investigational mIDH1 inhibitor targeting IDH1-mutant gliomas, conditions where treatment options remain limited. The decision to acquire safusidenib symbolizes Nuvation Bio's strategic approach to enhancing its portfolio — both expanding therapeutic options and addressing unmet patient needs.

The company plans to initiate a pivotal Phase 3 trial, the SIGMA study, aimed at evaluating safusidenib's efficacy in high-risk IDH1-mutant populations. Encouraging longer-term data from ongoing studies will also be shared at future medical meetings, promising to keep stakeholders informed about potential breakthroughs.

Future Outlook

As Nuvation Bio navigates through 2026, the focus will remain on patient-driven results and advancing its therapeutic offerings. The leadership team, headed by Dr. David Hung, is confident about reinforcing IBTROZI as a standard of care for advanced ROS1-positive NSCLC and is determined to expedite the development of safusidenib. The ongoing initiatives reflect a commitment to delivering impactful solutions for cancer patients globally.

Investors and interested parties can gain deeper insights into these developments during the forthcoming conference call scheduled for today at 4:30 PM ET. Stakeholders are encouraged to participate and learn about the financial trajectory and strategic vision that Nuvation Bio has set forth.

For additional information regarding Nuvation Bio and its portfolio, please visit Nuvation Bio's official website.